View DividendThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsFile Forge Technology 경영진경영진 기준 점검 0/4현재 CEO에 대한 정보가 충분하지 않습니다.핵심 정보 최고경영자n/a총 보수CEO 급여 비율n/aCEO 재임 기간no dataCEO 지분 보유율n/a경영진 평균 재임 기간데이터 없음이사회 평균 재임 기간데이터 없음최근 경영진 업데이트공시 • May 25Clarify Pharma PLC, Annual General Meeting, Jun 24, 2024Clarify Pharma PLC, Annual General Meeting, Jun 24, 2024. Location: the offices of fladgate llp, 16 great queen street, england, wc2b 5dg, london United Kingdom공시 • Jun 14Clarify Pharma PLC, Annual General Meeting, Jul 05, 2023Clarify Pharma PLC, Annual General Meeting, Jul 05, 2023, at 10:00 Coordinated Universal Time. Location: at the offices of Lomas & Co, Bridge House, 12 Market Street, Glossop, Derbyshire SK13 8AR London United KingdomBoard Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. was the last director to join the board, commencing their role in . The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • May 07Clarify Pharma PLC, Annual General Meeting, May 30, 2022Clarify Pharma PLC, Annual General Meeting, May 30, 2022, at 10:00 Coordinated Universal Time. Location: offices of Fladgate LLP, 16 Great Queen Street London United Kingdom모든 업데이트 보기Recent updates공시 • Jun 06Amirose London Limited completed the acquisition of File Forge Technology Plc (OFEX:FILE) in a reverse merger transaction.Amirose London Limited signed non-binding Heads of Terms to acquire File Forge Technology Plc (OFEX:FILE) for £0.07 million in a reverse merger transaction on March 20, 2025. The consideration consists of common equity of File Forge Technology Plc having a value of £5.01 million to be issued for common equity of Amirose London Limited. As part of consideration, £5.01 million is paid towards common equity of Amirose London Limited. Amirose London Limited executed a share purchase agreement to acquire File Forge Technology Plc (OFEX:FILE) for £0.07 million in a reverse merger transaction on April 25, 2025. File Forge has issued 100.190739 million shares to the shareholders of Amirose for £0.05 per New Ordinary Share. Amirose is seeking a listing on the Aquis Stock Exchange Growth Market via the reverse takeover in order to facilitate investments by investors and raise its profile with existing and future customers. Under the terms of the Acquisition Agreement, the Company will acquire Amirose through the issue of the Consideration Shares at an agreed valuation of £5,009,536. The Acquisition is conditional, inter alia, on the approval at the Extraordinary General Meeting of: i. the Waiver Resolution; ii. the Resolution to approve the Acquisition; and iii. the Resolutions to authorize the issue of the Consideration Shares and the Subscription Shares. Pursuant to the Acquisition and conditional on the approval of the Resolutions, all Directors will resign, and the Proposed Directors will be appointed on Admission. Michael Heath, Chief Executive Director, Aleksandra Binkowska, Non-Executive Chairperson, Mitchell Field, Non-Executive Director and David Battle, Independent Non-Executive Director. The Company has agreed with the Panel that Howard White, Ben White, Aleksandra Binkowska and Mitchell Field are ‘acting in concert’ in relation to the proposed acquisition by the Company of Amirose. Completion of the Acquisition was made subject to and conditional upon the satisfaction of certain conditions such conditions are required to be satisfied by no later than the long stop date, which has been agreed to be June 30, 2025. The transaction is subject to approval of offer by File Forge shareholders. It is expected that upon completion of the Proposed Acquisition, File Forge's name will be changed to Amirose London Holdings PLC. As of May 16, 2025 File Forge Technology's shareholder approved the transaction. As of May 21, 2025, On Admission, File Forge Technology PLC is to change its name to Amirose London Holdings PLC. Alfred Henry Corporate Finance Limited acted as financial advisor to File Forge Technology Plc and has charged £50,000 as advisor fees in the transaction. Glaisyers Solicitors LLP acted as legal advisor to File Forge Technology Plc. Computershare Investors Services (BVI) Ltd. Acted as registrar to File Forge Technology Plc. Amirose London Limited completed the acquisition of File Forge Technology Plc (OFEX:FILE) in a reverse merger transaction on June 6, 2025. The Company's change of name to Amirose London Holdings PLC will be effective once Companies House has issued a new certificate of incorporation reflecting the change of name. The ticker 'ALH' is effective immediately. From 9 June 2025, the Company's enlarged issued ordinary share capital will comprise 118,783,865 Ordinary Shares.공시 • Mar 21File Forge Technology Plc (OFEX:FILE) signed a letter of intent to acquire Amirose London Limited from Epoque Services Incorporated Limited for £5 million.File Forge Technology Plc (OFEX:FILE) signed non-binding Heads of Terms to acquire Amirose London Limited from Epoque Services Incorporated Limited for £5 million on March 20, 2025. The consideration consists of common equity of File Forge Technology Plc having a value of £5.01 million to be issued for common equity of Amirose London Limited. As part of consideration, £5.01 million is paid towards common equity of Amirose London Limited. The transaction is subject to approval of offer by File Forge shareholders. It is expected that upon completion of the Proposed Acquisition, File Forge's name will be changed to Amirose London Holdings PLC.New Risk • Mar 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended May 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (UK£208.0k market cap, or US$269.1k). Minor Risk Latest financial reports are more than 6 months old (reported May 2024 fiscal period end).공시 • May 25Clarify Pharma PLC, Annual General Meeting, Jun 24, 2024Clarify Pharma PLC, Annual General Meeting, Jun 24, 2024. Location: the offices of fladgate llp, 16 great queen street, england, wc2b 5dg, london United KingdomNew Risk • Mar 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended May 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (UK£683.6k market cap, or US$870.4k). Minor Risk Latest financial reports are more than 6 months old (reported May 2023 fiscal period end).공시 • Jun 14Clarify Pharma PLC, Annual General Meeting, Jul 05, 2023Clarify Pharma PLC, Annual General Meeting, Jul 05, 2023, at 10:00 Coordinated Universal Time. Location: at the offices of Lomas & Co, Bridge House, 12 Market Street, Glossop, Derbyshire SK13 8AR London United KingdomBoard Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. was the last director to join the board, commencing their role in . The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • May 07Clarify Pharma PLC, Annual General Meeting, May 30, 2022Clarify Pharma PLC, Annual General Meeting, May 30, 2022, at 10:00 Coordinated Universal Time. Location: offices of Fladgate LLP, 16 Great Queen Street London United KingdomCEOFile Forge Technology에는 CEO가 없거나 해당 데이터가 없습니다.View Ownership기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/06/05 16:42종가2025/06/05 00:00수익2024/05/31연간 수익2023/11/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스File Forge Technology Plc는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • May 25Clarify Pharma PLC, Annual General Meeting, Jun 24, 2024Clarify Pharma PLC, Annual General Meeting, Jun 24, 2024. Location: the offices of fladgate llp, 16 great queen street, england, wc2b 5dg, london United Kingdom
공시 • Jun 14Clarify Pharma PLC, Annual General Meeting, Jul 05, 2023Clarify Pharma PLC, Annual General Meeting, Jul 05, 2023, at 10:00 Coordinated Universal Time. Location: at the offices of Lomas & Co, Bridge House, 12 Market Street, Glossop, Derbyshire SK13 8AR London United Kingdom
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. was the last director to join the board, commencing their role in . The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • May 07Clarify Pharma PLC, Annual General Meeting, May 30, 2022Clarify Pharma PLC, Annual General Meeting, May 30, 2022, at 10:00 Coordinated Universal Time. Location: offices of Fladgate LLP, 16 Great Queen Street London United Kingdom
공시 • Jun 06Amirose London Limited completed the acquisition of File Forge Technology Plc (OFEX:FILE) in a reverse merger transaction.Amirose London Limited signed non-binding Heads of Terms to acquire File Forge Technology Plc (OFEX:FILE) for £0.07 million in a reverse merger transaction on March 20, 2025. The consideration consists of common equity of File Forge Technology Plc having a value of £5.01 million to be issued for common equity of Amirose London Limited. As part of consideration, £5.01 million is paid towards common equity of Amirose London Limited. Amirose London Limited executed a share purchase agreement to acquire File Forge Technology Plc (OFEX:FILE) for £0.07 million in a reverse merger transaction on April 25, 2025. File Forge has issued 100.190739 million shares to the shareholders of Amirose for £0.05 per New Ordinary Share. Amirose is seeking a listing on the Aquis Stock Exchange Growth Market via the reverse takeover in order to facilitate investments by investors and raise its profile with existing and future customers. Under the terms of the Acquisition Agreement, the Company will acquire Amirose through the issue of the Consideration Shares at an agreed valuation of £5,009,536. The Acquisition is conditional, inter alia, on the approval at the Extraordinary General Meeting of: i. the Waiver Resolution; ii. the Resolution to approve the Acquisition; and iii. the Resolutions to authorize the issue of the Consideration Shares and the Subscription Shares. Pursuant to the Acquisition and conditional on the approval of the Resolutions, all Directors will resign, and the Proposed Directors will be appointed on Admission. Michael Heath, Chief Executive Director, Aleksandra Binkowska, Non-Executive Chairperson, Mitchell Field, Non-Executive Director and David Battle, Independent Non-Executive Director. The Company has agreed with the Panel that Howard White, Ben White, Aleksandra Binkowska and Mitchell Field are ‘acting in concert’ in relation to the proposed acquisition by the Company of Amirose. Completion of the Acquisition was made subject to and conditional upon the satisfaction of certain conditions such conditions are required to be satisfied by no later than the long stop date, which has been agreed to be June 30, 2025. The transaction is subject to approval of offer by File Forge shareholders. It is expected that upon completion of the Proposed Acquisition, File Forge's name will be changed to Amirose London Holdings PLC. As of May 16, 2025 File Forge Technology's shareholder approved the transaction. As of May 21, 2025, On Admission, File Forge Technology PLC is to change its name to Amirose London Holdings PLC. Alfred Henry Corporate Finance Limited acted as financial advisor to File Forge Technology Plc and has charged £50,000 as advisor fees in the transaction. Glaisyers Solicitors LLP acted as legal advisor to File Forge Technology Plc. Computershare Investors Services (BVI) Ltd. Acted as registrar to File Forge Technology Plc. Amirose London Limited completed the acquisition of File Forge Technology Plc (OFEX:FILE) in a reverse merger transaction on June 6, 2025. The Company's change of name to Amirose London Holdings PLC will be effective once Companies House has issued a new certificate of incorporation reflecting the change of name. The ticker 'ALH' is effective immediately. From 9 June 2025, the Company's enlarged issued ordinary share capital will comprise 118,783,865 Ordinary Shares.
공시 • Mar 21File Forge Technology Plc (OFEX:FILE) signed a letter of intent to acquire Amirose London Limited from Epoque Services Incorporated Limited for £5 million.File Forge Technology Plc (OFEX:FILE) signed non-binding Heads of Terms to acquire Amirose London Limited from Epoque Services Incorporated Limited for £5 million on March 20, 2025. The consideration consists of common equity of File Forge Technology Plc having a value of £5.01 million to be issued for common equity of Amirose London Limited. As part of consideration, £5.01 million is paid towards common equity of Amirose London Limited. The transaction is subject to approval of offer by File Forge shareholders. It is expected that upon completion of the Proposed Acquisition, File Forge's name will be changed to Amirose London Holdings PLC.
New Risk • Mar 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended May 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (UK£208.0k market cap, or US$269.1k). Minor Risk Latest financial reports are more than 6 months old (reported May 2024 fiscal period end).
공시 • May 25Clarify Pharma PLC, Annual General Meeting, Jun 24, 2024Clarify Pharma PLC, Annual General Meeting, Jun 24, 2024. Location: the offices of fladgate llp, 16 great queen street, england, wc2b 5dg, london United Kingdom
New Risk • Mar 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended May 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (UK£683.6k market cap, or US$870.4k). Minor Risk Latest financial reports are more than 6 months old (reported May 2023 fiscal period end).
공시 • Jun 14Clarify Pharma PLC, Annual General Meeting, Jul 05, 2023Clarify Pharma PLC, Annual General Meeting, Jul 05, 2023, at 10:00 Coordinated Universal Time. Location: at the offices of Lomas & Co, Bridge House, 12 Market Street, Glossop, Derbyshire SK13 8AR London United Kingdom
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. was the last director to join the board, commencing their role in . The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • May 07Clarify Pharma PLC, Annual General Meeting, May 30, 2022Clarify Pharma PLC, Annual General Meeting, May 30, 2022, at 10:00 Coordinated Universal Time. Location: offices of Fladgate LLP, 16 Great Queen Street London United Kingdom